PainReform
PRFX
#11164
Rank
HK$21.13 M
Marketcap
HK$6.04
Share price
-5.09%
Change (1 day)
-16.48%
Change (1 year)

P/E ratio for PainReform (PRFX)

P/E ratio as of November 2026 (TTM): -0.0008

According to PainReform's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.000773551. At the end of 2022 the company had a P/E ratio of -0.0504.

P/E ratio history for PainReform from 2020 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-0.0504-71.97%
2021-0.1797-81.65%
2020-0.9795

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
OPKO Health
OPK
-19.0 2,456,105.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Onconova Therapeutics
ONTX
-0.9953 128,566.37%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.